	Rituximab
Anti-CD20
Chronic ITP
Refractory ITP
	platelet count
median time
response
platelets
results
patients
follow-up
minimal response
rituximab therapy
dose
chronic
months
treatment
range
weeks
refractory ITP
long-term side effects
immune thrombocytopenic purpura
immunosuppressive therapy
low platelet
long-term complications
ITP
disease
splenectomy
study
group
Bcell
probability
cells
low
time

